Company Description
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally.
The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis.
In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension.
Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting.
The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Country | United States |
IPO Date | Aug 11, 2009 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 91 |
CEO | A. J. Kazimi MBA |
Contact Details
Address: 2525 West End Avenue Nashville, Tennessee United States | |
Website | https://www.cumberlandpharma.com |
Stock Details
Ticker Symbol | CPIX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001087294 |
CUSIP Number | 230770109 |
ISIN Number | US2307701092 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
A. J. Kazimi MBA | Founder, Chairman, President & Chief Executive Officer |
John Michael Hamm C.M.A. | Vice President & Chief Financial Officer |
Adam S. Mostafa | Managing Director |
Chris T. Bitterman | Vice President of Sales & Marketing |
Erin Smith Gull | Senior Corporate Relations Associate |
James Lowrance Herman | Executive Vice President of National Accounts & Chief Compliance Officer |
Jean W. Marstiller | Senior Vice President of Administrative Services & Corporate Secretary |
Todd M. Anthony | Vice President of Organizational Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 09, 2024 | 8-K | Current Report |
Dec 05, 2024 | 4 | Filing |
Dec 05, 2024 | 4 | Filing |
Dec 05, 2024 | 4 | Filing |
Dec 05, 2024 | 4 | Filing |
Nov 08, 2024 | 10-Q | Quarterly Report |
Nov 07, 2024 | 8-K | Current Report |
Nov 06, 2024 | 8-K | Current Report |
Nov 05, 2024 | 4 | Filing |
Nov 05, 2024 | 4 | Filing |